EpimAb Biotherapeutics Revenue and Competitors

Shanghai,

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • EpimAb Biotherapeutics's estimated annual revenue is currently $7.8M per year.(i)
  • EpimAb Biotherapeutics's estimated revenue per employee is $155,000

Employee Data

  • EpimAb Biotherapeutics has 50 Employees.(i)
  • EpimAb Biotherapeutics grew their employee count by 2% last year.

EpimAb Biotherapeutics's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is EpimAb Biotherapeutics?

EpimAb Biotherapeutics, Inc., is a China-based, privately held, start-up company founded in 2015 that is developing a portfolio of novel bi-specific antibodies in oncology and immune-oncology. All bispecifics are based on a proprietary platform, FIT-Ig (Fabs in Tandem). Multiple FIT-Igs have already been successfully generated binding to small, large, soluble or membrane-bound antigens with biochemical and biophysical properties similar to their parent monospecific antibodies. The first molecule, EMB-01, is a cMET/EGFR-inhibitor, that is in CMC development in collaboration with WuXi Apptec. EpimAb also has concluded licensing arrangements, e.g. with Kymab and Innovent Biologics, and is open to further partnerships. EpimAb has successfully concluded a Series A round of $25 MM with a consortium of international investors.

keywords:N/A

N/A

Total Funding

50

Number of Employees

$7.8M

Revenue (est)

2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$8.8M50-7%N/A
#2
$7.9M512%N/A
#3
$11.5M52-4%N/A
#4
$5.6M520%N/A
#5
$9.8M540%N/A